Page 89 - 《中国药房》2023年14期

tion of tyrosine kinases by sunitinib associated with focal drome after bevacizumab：case report and literature review
segmental glomerulosclerosis lesion in addition to throm‐ [J]. Am J Kidney Dis，2007，49（2）：e23-e29.
botic microangiopathy[J]. Nephrol Dial Transplant，2010， [21] CHOUEIRI T K，POWLES T，BUROTTO M，et al. Nivo-
25（3）：1001-1003. lumab plus cabozantinib versus sunitinib for advanced
[ 8 ] JHAVERI K D，FLOMBAUM C D，KROOG G，et al. renal-cell carcinoma[J]. N Engl J Med，2021，384（9）：
Nephrotoxicities associated with the use of tyrosine kinase 829-841.
inhibitors：a single-center experience and review of the [22] KOLLMANNSBERGER C，BJARNASON G，BURNETT
literature[J]. Nephron Clin Pract，2011，117（4）：c312- P，et al. Sunitinib in metastatic renal cell carcinoma：
c319. recommendations for management of noncardiovascular
[ 9 ] LIU Y C，CHANG P M，LIU C Y，et al. Sunitinib-induced toxicities[J]. Oncologist，2011，16（5）：543-553.
nephrotic syndrome in association with drug response in a [23] MOTZER R J，HUTSON T E，TOMCZAK P，et al. Ove-
patient with Xp11.2 translocation renal cell carcinoma[J]. rall survival and updated results for sunitinib compared
Jpn J Clin Oncol，2011，41（11）：1277-1281. with interferon Alfa in patients with metastatic renal cell
[10] TAKAHASHI D，NAGAHAMA K，TSUURA Y，et al. carcinoma[J]. J Clin Oncol，2023，41（11）：1965-1971.
Sunitinib-induced nephrotic syndrome and irreversible [24] KHANNA R. Clinical presentation & management of glo‐
renal dysfunction[J]. Clin Exp Nephrol，2012，16（2）： merular diseases：hematuria，nephritic & nephrotic syn‐
310-315. drome[J]. Mo Med，2011，108（1）：33-36.
[11] TURAN N，BENEKLI M，OZTURK S C，et al. Sunitinib [25] KIM E，KOO Y J，LEE D H. Bevacizumab-associated ne‐
and sorafenib-induced nephrotic syndrome in a patient phrotic syndrome in a woman with unilateral renal age-
with gastrointestinal stromal tumor[J]. Ann Pharmacother， nesis[J]. Am J Ther，2020，28（3）：368-369.
2012，46（10）：e27. [26] GUREVICH F，PERAZELLA M A. Renal effects of anti-
[12] PALLOTTI M C，PANTALEO M A，NANNINI M，et al. angiogenesis therapy：update for the internist[J]. Am J
Development of a nephrotic syndrome in a patient with Med，2009，122（4）：322-328.
gastrointestinal stromal tumor during a long-time treat‐ [27] GOLDBERG R J，NAKAGAWA T，JOHNSON R J，et al.
ment with sunitinib[J]. Case Rep Oncol，2012，5（3）： The role of endothelial cell injury in thrombotic microan‐
651-656. giopathy[J]. Am J Kidney Dis，2010，56（6）：1168-1174.
[13] JHA P K，VANKALAKUNTI M，SIDDINI V，et al. Suni‐ [28] PATEL T V，MORGAN J A，DEMETRI G D，et al. A
tinib induced nephrotic syndrome and thrombotic microan‐ preeclampsia-like syndrome characterized by reversible
giopathy[J]. Indian J Nephrol，2013，23（1）：67-70. hypertension and proteinuria induced by the multitargeted
[14] RUEBNER R L，COPELOVITCH L，EVAGELIOU N F， kinase inhibitors sunitinib and sorafenib[J]. J Natl Cancer
et al. Nephrotic syndrome associated with tyrosine kinase Inst，2008，100（4）：282-284.
inhibitors for pediatric malignancy：case series and review [29] OLAYA-C M，GARRIDO M，HERNANDEZ-LOSA J，et
of the literature[J]. Pediatr Nephrol，2014，29（5）：863-869. al. The umbilical cord，preeclampsia and the VEGF family
[15] QUINTYNE K I，NEENAN T，CASSERLY L，et al. Un‐ [J]. Int J Womens Health，2018，10：783-795.
common side effect with a commonly used targeted agent： [30] EDDY A C，BIDWELL G L，GEORGE E M. Proan-
sunitinib-induced nephrotic syndrome in a patient with giogenic therapeutics for preeclampsia[J]. Biol Sex Differ，
metastatic renal cell carcinoma[J]. BMJ Case Rep，2014， 2018，9（1）：36.
2014：bcr2013201183. [31] 中国医促会泌尿健康促进分会，中国研究型医院学会泌
[16] 吴小芳，徐缓，李孜. 1例舒尼替尼致肾脏血栓性微血管 尿外科学专业委员会. 肾癌分子靶向药舒尼替尼用药安
病变及肾病综合征报道[J]. 临床药物治疗杂志，2019，17 全共识[J]. 现代泌尿外科杂志，2020，25（10）：862-869.
（10）：85-89. [32] HOUK B E，BELLO C L，MICHAELSON M D，et al.
[17] HAKSÖYLER V，PAYDAŞ S. An interesting case： Exposure-response of sunitinib in metastatic renal cell car‐
sunitinib-induced microangiopathic hemolytic anemia and cinoma（mRCC）：a population pharmacokinetic/pharmaco‐
nephrotic syndrome[J]. Turk J Haematol，2021，38（2）： dynamic（PKPD）approach[J]. J Clin Oncol，2007，25
163-165. （18_suppl）：5027.
[18] ZONOOZI S，PALMER M，URSINA T，et al. Worsening [33] HENG D Y C，KOLLMANNSBERGER C. Sunitinib[J].
membranous nephropathy in a patient with GIST treated Recent Results Cancer Res，2010，184：71-82.
with sunitinib[J]. BMJ Case Rep，2021，14（8）：e243567. [34] Kidney Disease：Improving Global Outcomes （KDIGO）
[19] NIETO-RÍOS J F，GARCÍA-PRADA C A，ARISTIZABAL- Glomerular Diseases Work Group. KDIGO 2021 clinical
ALZATE A，et al. Nephrotic syndrome as a manifestation practice guideline for the management of glomerular di-
of thrombotic microangiopathy due to long-term use of seases[J]. Kidney Int，2021，100（4S）：S1-S276.
sunitinib[J]. Nefrologia（Engl Ed），2022，42（6）：722-726. （收稿日期：2022-12-05 修回日期：2023-06-16）
[20] GEORGE B A，ZHOU X J，TOTO R. Nephrotic syn‐ （编辑：陈 宏）

中国药房 2023年第34卷第14期 China Pharmacy 2023 Vol. 34 No. 14 · 1743 ·